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In pemphigus vulgaris (PV), IgG autoantibodies against the ectodomain of desmoglein 3 (Dsg3) have been shown to be directly
responsible for the loss of keratinocyteadhesion. The aim of the present study was to study the eﬀect of the B cell depleting
anti-CD20 monoclonal antibody, rituximab, on the proﬁle of pathogenic IgG against distinct regions of the Dsg3 ectodomain in
22PV patients who were followed up clinically and serologically by Dsg3 ELISA over 12-24 months. Prior to rituximab, all the
22PV patients showed IgG against Dsg3 (Dsc3EC1-5). Speciﬁcally, 14/22 showed IgG reactivity against the Dsg3EC1 subdomain,
5/22 patients against Dsg3EC2, 7/22 against Dsg3EC3, 11/22 against Dsg3EC4, and 2/22 against Dsg3EC5. Within 6 months
after rituximab, all the patients showed signiﬁcant clinical improvement and reduced IgG against Dsg3 (5/22) and the various
subdomains, that is, Dsg3EC1 (7/22), Dsg3EC2 (3/22), Dsg3EC3 (2/22), sg3EC4 (2/22), and Dsg3EC5 (0/22). During the entire
observation period, 6/22 PV patients experienced a clinical relapse which was associated with the reappearance of IgG against
previously recognized Dsg3 subdomains, particularly against the Dsg3EC1. Thus, in PV, rituximab only temporarily depletes
pathogenic B cell responses against distinct subdomains of Dsg3 which reappear upon clinical relapse.
1.Introduction
Pemphigus vulgaris (PV) is a life-threatening autoimmune
blistering disease caused by IgG autoantibodies (auto-Ab)
against the extracellular domain (ECD) of desmoglein 3
(Dsg3) and Dsg1, desmosomal adhesion molecules present
on epidermal keratinocytes [1]. Auto-Ab production in PV
is polyclonal, and in active PV, most auto-Abs are of the IgG4
subclass [2, 3]. It has been postulated that auto-Ab against
Dsg3 and Dsg1 primarily target the NH2-terminal portion of
theDsg3ectodomain,thatis,theDsg3EC1subdomain[4–8].
The EC1 domains of Dsg3 and Dsg1, respectively, according
to morphologic studies in desmosomes, are increasingly rec-
ognized as the part of the desmosomal cadherin ectodomain
which is involved in Dsg transinteraction [9]. Moreover,
it seems that IgG auto-Ab reactivity against the Dsg3EC1
domain correlates with active disease in PV although
the titers of the auto-Ab do not show a strict correlation
withdiseaseactivity[10,11].Recently,wefoundasigniﬁcant
correlation between IgG reactivity against Dsg3EC1 and
the extent of clinical involvement in PV [8]. IgG against
the Dsg3EC1 was seen preferentially in PV patients with
mucocutaneous involvement but not in patients with either
mucosal or skin involvement only [8].
IgG auto-Ab from pemphigus sera cause loss of adhesion
of human skin in vivo and in vitro [12, 13]. Because auto-
Ab in pemphigus are directed against desmosomal adhesion
molecules, it was suggested that these autoantibodies might
directly interfere with Dsg transinteraction binding sites
[14–17]. Previous studies showed that IgG against the
NH2-terminus of the Dsg3 ectodomain is pathogenic [18].
Aﬃnity-puriﬁed IgG of sera from PV patients injected into
neonatal mice which were reactive with the EC1 and EC2 of
Dsg3, respectively, induced suprabasilar acantholysis, while2 Dermatology Research and Practice
IgG reactive with the EC3-5 of Dsg3 did not [10]. AK23,
a mouse monoclonal Ab against Dsg3 which targets the
predicted binding motif of the Dsg3EC1, has been shown to
be pathogenic in vivo whereas IgG targeting other regions
of the Dsg3 ectodomain was not [5, 19]. AK23 directly
interferes with homophilic adhesion of two Dsg3 proteins
[20] which supports the hypothesis that auto-Ab from
PV patients directly inhibit Dsg3-mediated epidermal cell
adhesion [21].
Apart from major advances in our understanding of the
immune pathogenesis of pemphigus, therapeutic options in
cases of recalcitrant pemphigus are rather limited. The stan-
dardimmunosuppressivetreatmentofpemphigusconsistsof
systemic glucocorticoids and adjuvant immunosuppressive
drugs which induce partial or complete clinical remission
in the majority of the patients. In the remaining refractory
cases, the B-cell depleting anti-CD20 monoclonal Ab, rit-
uximab, has been recently introduced as a highly eﬀective
rescue medication. Rituximab is a chimeric human/mouse
IgG1 monoclonal ab and is directed against CD20, a pan B
cell glycoprotein on B lymphocytes from the preB cell to the
preplasma-cell stage. Among several mechanisms involved in
B cell killing, rituximab exerts B cell cytolytic activity mainly
through ab-dependent cell-mediated cytotoxicity. A plethora
of case series and two prospective clinical trials strongly
suggest that rituximab is highly eﬀective in recalcitrant
pemphigus [22].
In the present study, the impact of rituximab treatment
on the proﬁle of Dsg3-speciﬁc auto-Ab was studied in a
cohort of 22 well-characterized patients with PV. During a
12 to 24 months’ observation period, IgG reactivity against
distinct regions of the Dsg3 ectodomain was correlated
with clinical parameters such as involvement of body
surface area and mucosal surfaces. Our ﬁndings suggest
that rituximab treatment only temporarily depletes distinct
IgG reactivity against the Dsg3 ectodomain and that the
reappearance of such auto-ab is associated with clinical
relapses. In particular, IgG reactivity against the NH2-
terminal EC1 subregion of the Dsg3 ectodomain was pref-
erentially detected in PV patients who experienced a clinical
relapse.
2. Patientsand Methods
2.1. PV Patients. Serum samples were obtained from 22
adult patients with PV who were seen at the Dermatology
Departments at the Universities of Cologne, Marburg, and
Rouen. Patients gave written consent to participate in this
study which was adherent to the Declaration of Helsinki
Guidelines and which was approved by the local Ethics Com-
mittees. The clinical diagnosis of PV was conﬁrmed by (1)
histopathology (suprabasal acantholytic blisters), (2) direct
immunoﬂuorescence microscopy (epidermal intercellular
IgG and/or C3 deposits in perilesional skin), (3) detection
of serum IgG auto-ab by indirect immunoﬂuorescence
microscopy (intercellular IgG binding to epithelial cells of
monkey esophagus), and (4) by ELISA with recombinant
Dsg3 and Dsg1. All the 22PV patients (mean age: 51.3 ±
15.7 years; 11 females and 11 males) mainly presented with
mucocutaneousinvolvementandelevatedanti-DsgIgGtiters
(Table 1) despite ongoing (> 3 months) immunosuppressive
treatment with systemic corticosteroids (initially 1mg/kg/d;
tapered logarithmically upon clinical response) and the
immunosuppressive agents, azathioprine (100–150mg/day)
or mycophenolate mofetil (1-2g/day), respectively (Table 1).
The clinical extent and severity of PV was classiﬁed
according to the number of blisters or erosions as either
mucosal or cutaneous involvement (the later was quantitated
by the body surface area; BSA). All the PV patients were
treated i.v. with rituximab at 375mg/m2 on days 0, 7, 14,
and 21 and were kept on an immunosuppressive treatment
regimen consisting of prednisolone and azathioprine or
mycophenolate mofetil, respectively.
2.2. ELISA with Dsg3 Recombinants. Recombinants repre-
senting the entire Dsg3 ectodomain (Dsg3EC1-5) and dis-
tinct subregions of the Dsg3 ectodomain, that is, Dsg3EC1-
5 (aa 1-566), Dsg3EC1 (aa 1-161), Dsg3EC2 (aa 87-227),
Dsg3EC3 (aa 184-349), Dsg3EC4 (aa 313-451) and Dsg3EC5
(aa 424-566) were produced in an eukaryotic baculovirus
expression system and were puriﬁed using Nickel-NTA as
previously described [8, 23]. By ELISA, the patients’ sera
were tested for IgG reactivity against the Dsg3 ectodomain
( D s g 3 E C 1 - 5 )a sw e l la sI g Gr e a c t i v i t ya g a i n s ts u b d o m a i n so f
theextracellularportionofDsg3asrecentlydescribed[8,23].
In short, the recombinant Dsg proteins were immobilized on
microtiter plates and were incubated with the PV patients’
sera at a dilution of 1:50. IgG binding was visualized as
optical density (OD) at 405nm. Samples were run at least
in duplicate and OD’s were expressed as mean values. The
threshold for IgG binding of the Dsg3 recombinants in
the ELISA yielded an OD value of 0.376 as determined by
a ROC curve generated for Dsg3EC1-5 [23]. OD values
above the cutoﬀ point deﬁned positive IgG reactivity, while
IgG reactivity below the cutoﬀ point was considered to be
negative.
2.3. Scoring of Disease Activity in Pemphigus. Scores for
mucosal involvement were set as follows: 0, if the patient
had no mucosal involvement, 1 point for each additional
location of blisters (i.e., oral, dysphagia, genital, conjunctival
involvement) and additionally, 1 point for >3 erosions with
a diameter >2mm. Skin involvement was assessed by body
surface area and was expressed as percentage of aﬀected area.
3. Results
3.1. Clinical Response to Rituximab of the Studied PV
Patients. All the 22PV patients showed a marked clinical
response to rituximab treatment which was expressed as
dramatically reduced mucosal (baseline: 4.60 ± 1.96; 1.59
± 1.80 after 6 months) and BSA (baseline: 11.05 ± 13.14;
0.53 ± 1.01 after 6 months) scores within six months
after treatment (Figure 1(a)). Among the studied patients,
18/22 (81.8%) had skin involvement and 18/22 (81.8%)
mucosal involvement. Except for patient PV6 whose clinical
symptoms were unknown, all the PV patients had mucosalDermatology Research and Practice 3
Table 1: Clinical and immunological characteristics of the pemphigus vulgaris (PV) patients on adjuvant treatment with rituximab.
Patients Treatment(1) Sex Age Clinical phenotype of PV(2) Severity(3) IgG autoantibody proﬁle(4)
Mucosa BSA (%) Anti-Dsg1 Anti-Dsg3
PV1 Pred., MMF, Dapson m 53 mucocutaneous 2 3 103 549
PV2 Pred., MMF, MTX m 67 mucocutaneous 4 1 10 484
PV3 Pred., MMF, Azathioprin f 69 mucosal 7 0 neg 810
PV4 Pred. f 69 no mucosal involvement 0 4 163 2368
PV5 Pred. MMF, Azathioprin f 37 mucocutaneous 3 5 183 94
PV6 n.d. m 48 n.d. n.d. n.d. 979 906
PV7 Pred., MMF m 50 mucocutaneous 8 1 82 201
PV8 Pred., MMF, Dapson f 23 mucocutaneous 2 12 357 145
PV10 Pred., MMF f 57 mucosal 6 0 3 124
PV11 Pred., MMF, MTX f 28 mucosal 5 0 6 229
PV12 Pred., MMF f 54 mucocutaneous 7 5 199 175
PV13 n.d. m 62 mucocutaneous 7 10 78 220
PV14 Pred. m 79 mucocutaneous 6 10 170 200
PV15 Pred. m 36 mucocutaneous 4 60 155 201
PV16 n.d. m 64 mucocutaneous 6 20 163 58
PV17 Pred. f 51 mucocutaneous 5 10 181 209
PV18 Pred. f 70 mucocutaneous 4 10 neg 143
PV19 n.d. m 59 mucocutaneous 4 10 98 156
PV20 Pred. m 38 mucocutaneous 4 20 36 138
PV21 Pred. f 41 mucocutaneous 5 10 18 119
PV22 Pred. m 24 mucocutaneous 4 20 138 135
PV23 Pred. f 50 Mucocutaneous 5 10 176 163
(1)Systemic prednisolone (Pred) was administered throughout the observation period and was logarithmically tapered upon clinical reponse to treatment;
azathioprine (AZA) or mycophenolate mofetil (MMF), respectively, was also administered throughout the observation period. n.d., not determined.
(2)Before treatment with rituximab.
(3)Determined by the extent of cutaneous involvement as body surface area (BSA) and the extent of mucosal involvement.
(4)Determined by enzyme-linked immunosorbent assay (ELISA) with recombinant desmoglein (Dsg) 1 and 3; optical densities are expressed as PIV (protein
index value).
(5)PIV cutoﬀ is 20.
involvement. Clinical improvement to rituximab was also
monitored as a marked reduction of systemic treatment with
prednisolone from 0.63 ± 0.60mg/kg body weight (baseline)
to 0.20 ± 0.17mg/kg body weight (6 months after rituximab
treatment)(Figure 1(a)).Noteworthy,6/22PVpatientsexpe-
rienced a relapse 12 to 24 months after rituximab treatment.
3.2. IgG Titers against Distinct Dsg3 Subdomains and Disease
Activity of the PV Patients Are Reduced upon Treatment
with Rituximab. IgG auto-ab of the 22PV patients against
the Dsg3 ectodomain and its subdomains was analysed
by ELISA during the course of the disease (Figure 1(b)).
Prior to treatment with rituximab, all PV patients showed
IgG reactivity against at least some part of the entire
Dsg3 ectodomain (Dsg3EC1-5), 14/22 showed IgG reactivity
against the Dsg3EC1 subdomain, 5/22 patients against
Dsg3EC2, 7/22 against Dsg3EC3, 11/22 against Dsg3EC4,
and 2/22 against Dsg3EC5. Within 6 months after treatment,
there was a marked reduction of IgG reactivity against the
Dsg3 ectodomain as well as against distinct subdomains
(Figure 1(b)).Becauseoftheavailabilityofpatientsseraatall
time points, the persistence or disappearance of IgG against
distinct Dsg3 regions upon treatment with rituximab was
s t u d i e di nm o r ed e t a i li n1 6P Vp a t i e n t s .
Among these patients, the number of patients with IgG
reactivity against the recombinant proteins of Dsg3 of less
than 80% of the initial level was studied 6 and 12 months
after rituximab (Figure 2). Initially, 16PV patients showed
IgG reactivity against Dsg3EC1-5, 11 against Dsg3EC1, 4
against Dsg3EC2, 5 against Dsg3EC3, 6 against Dsg3EC4,
and 2 against Dsg3EC5. Of the 16 patients, a total of 11
showed reduced (by more than 80%) IgG reactivity against
the Dsg3 ectodomain (Dsg3EC1-5): Six months after treat-
ment with rituximab, IgG reactivity against Dsg3EC1 was
more than 80% reduced in 4/11 patients, against Dsg3EC2
in 1/4 PV patients, against Dsg3EC3 in 3/5 patients against
Dsg3EC4 in 4/6, and against Dsg3EC5 in 2/5 patients. Twelve
months after treatment with rituximab, IgG reactivity of less
than80% oftheinitial valuewasnoticed in 11/16 (Dsg3EC1-
5), 4/11 (Dsg3EC1), 1/4 (Dsg3EC2), 2/5 (Dsg3EC3), 3/6
(Dsg3EC4) and 2/2 (Dsg3EC5) PV patients. Speciﬁcally, the
impact of rituximab treatment on IgG reactivity against
distinct Dsg3 subdomains is given in Table 2 (0 and 6
months).4 Dermatology Research and Practice
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Figure 1: Rituximab (Rtx) treatment of pemphigus vulgaris (PV)
patients leads to clinical improvement of skin and mucosal lesions
and is accompanied by decreased IgG titers against distinct regions
of desmoglein 3 (Dsg3) ectodomain. Treatment with Rtx of 22PV
patients led to a signiﬁcant improvement of mucosal and skin
lesions and is expressed as reduced mucosal and body surface area
(BSA) scores within 6 months after treatment (Figure 1(a)). In the
same way, the dose of prednisolone was reduced (Figure 1(a)). By
enzyme-linked immunosorbent assay, there was clearly a reduction
of IgG reactivity against the Dsg3 ectodomain (Dsg3EC1-5) and
deﬁned regions of the Dsg3 ectodomain (Figure 1(b)). The number
of studied patients or sera, respectively, is given in parenthesis. Rtx
(time when rituximab was administered).
3.3. Reappearance of IgG against Distinct Regions of the
Dsg3 Ectodomain in PV Patients with Clinical Relapses after
Rituximab Treatment. Six of the 22PV patients treated with
rituximab showed a clinical relapse 12 months (n = 3;
PV3, PV5, PV6) or 18 months (n = 3; PV13, PV19, PV23),
respectively, after rituximab treatment (Table 3). Clinical
relapses were deﬁned as newly arisen mucosal or cutaneous
lesions which persisted for more than 7 days. All the relapsed
PV patients showed increased IgG auto-ab against at least
some part of the entire Dsg3 ectodomain (Figure 3)b u tw i t h
individual patterns of IgG recognition of Dsg3 subdomains
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Figure 2: IgG reactivity against desmoglein 3 (Dsg3) subdomains
in pemphigus vulgaris (PV) patients on rituximab (Rtx). Illustrated
isthenumberofPVpatientsshowingIgGagainstDsg3subdomains
before and 6 and 12 months after treatment with Rtx, respectively.
(Table 3). In the individual PV patients, clinical relapses were
associated with the reappearance of distinct auto-ab proﬁles
(Figure 3).Fourofthe6relapsedPVpatientshadIgGagainst
the Dsg3EC1 subdomain prior to rituximab treatment, that
is, patients PV3, PV6, PV13, and PV19 (Figure 3). In these
PV patients, IgG auto-ab against Dsg3EC1 decreased (PV6,
PV13) or remained constant (P3, P19) upon rituximab
treatment. Noteworthy, in all these patients, IgG against the
Dsg3EC1 persisted until or reappeared at the time of clinical
relapse. PV patient PV23 did not initially show IgG against
Dsg3EC1butatthetimeofrelapse18monthsafterrituximab
treatment.
Only PV patient PV5 had a diﬀerent auto-ab proﬁle
and showed IgG against Dsg3EC3 and Dsg3EC4 prior to
rituximab. At the time of clinical relapse 12 months later, he
showed IgG against Dsg3EC4 which exceeded pretreatment
levels (Figure 3). In patient PV5, IgG against Dsg3EC1 was
not detected at the time of clinical relapse.
Noteworthy, some of these patients showed IgG reac-
tivity against distinct Dsg3 subdomains in addition to IgG
against Dsg3EC1 at the time of clinical relapse. Patient PV3
showed IgG against Dsg3EC1, Dsg3EC2, and Dsg3EC4 whenDermatology Research and Practice 5
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Figure 3: Association of clinical relapses of rituximab (Rtx)-treated pemphigus vulgaris (PV) patients and the reappearance of IgG against
distinct regions of the Dsg3 ectodomain. Three of the 6 PV patients (PV3, PV6, PV23) showed an increase of IgG reactive with the Dsg3EC1
subdomainuponclinicalrelapseafterRtxtherapy.PatientPV13showedincreasedserumlevelsofIgGagainsttheDsg3EC4subdomainwhile
patients PV5 and PV19 did not show altered IgG levels against any of the studied Dsg3 subdomains upon clinical relapse.6 Dermatology Research and Practice
Table 2: Proﬁle of desmoglein 3 (Dsg3)-speciﬁc IgG autoantibodies of the pemphigus vulgaris (PV) patients before and 6 months after
treatment with rituximab (Rtx).
Dsg3EC1 Dsg3EC2 Dsg3EC3 Dsg3EC4 Dsg3EC5
T i m e p o i n t 0606060606
P V 1 ++++++−−−−
PV2 + + + + −−−−−−
PV3 + + − + −−−+ −−
PV4 + −−−+++−−−
PV5 −−−−+ − ++−−
PV6 + −−−−−−−−−
PV7 + + + + −−−−−−
PV8 −−−−+ −−−−−
PV10 −−−+ −−+ −−−
PV11 + + −−−−−−−−
PV12 + + + − ++++−−
PV13 + −−−−−+ −−−
PV14 + − + −−−+ − + −
PV15 −−−−+ −−−−−
PV16 −−−−−−++−−
PV17 + + −−−−−−−−
PV18 −−−−−−+ −−−
PV19 + + −−−−−−−−
PV20 + + −−−−−−−−
PV21 + + −−+++−−−
PV22 −−−−−−+ −−−
PV23 −−−−−−+++−
Table 3: Synopsis of the IgG autoantibody proﬁle of the pemphigus vulgaris (PV) patients prior to rituximab (preRtx) treatment and at the
time of clinical relapse (CR).
IgG against extracellular subdomains of Dsg3
Dsg3EC1 Dsg3EC2 Dsg3EC3 Dsg3EC4 Dsg3EC5
Time point preRtx 6
months
CR preRtx 6
months
CR preRtx 6
months
CR preRtx 6
months
CR preRtx 6
months
CR
PV3 (CR, months 12) + + + − + + − − −− + + − − −
PV5 (CR, months 12) − − −− − ++ − ++ + + − − −
PV6 (CR, months 12) + − + − − −− − −− − −− − −
PV13 (CR, months 18) + − + − − −− − − + − + − − −
PV19 (CR, months 18) + + + − − −− − −− − + − − −
PV23 (CR, months 18) − − + − − −− − − + + ++ − −
he developed new cutaneous lesions and patient PV5 had
IgG against Dsg3EC1, Dsg3EC2, Dsg3EC3, and Dsg3EC4
when he relapsed. Finally, PV patient PV23 showed IgG
against Dsg3EC1 and Dsg3EC4 upon clinical relapse. None
of the 6 PV patients showed IgG against the COOH-
terminal Dsg3EC5 subdomain at the time of clinical relapse
(Figure 3).
4. Discussion
The present study strongly suggests that rituximab, a mon-
oclonal antibody against CD20 on B cells, does not perma-
nently deplete pathogenic B cell responses against Dsg3 in
patients with PV, a potentially lethal autoimmune bullous
disorder of skin and mucosa. Here, a total of 22 patients
with refractory PV were treated with rituximab which had
been recently identiﬁed as a potent treatment in refractory
PV [24, 25]. Speciﬁcally, these patients did not adequately
respond to standard immunosuppressive treatment consist-
ing of high dose systemic corticosteroids combined with the
immunosuppressiveadjuvants,azathioprine,ormycopheno-
late mofetil, respectively.
In the cohort of studied patients, all of the 22PV patients
initially showed an excellent clinical response to rituximabDermatology Research and Practice 7
treatment. However, within 12–18 months after rituximab
treatment, 6/22PV patients experienced a clinical relapse
which was associated with the persistence or reappearance
of IgG auto-ab against distinct extracellular subdomains
of Dsg3, the major autoantigen of PV (Figure 3). The
majority, that is, 5/6 of the relapsed PV patients, showed the
reappearance of IgG against the NH2-terminal subdomain
Dsg3EC1 which has been previously identiﬁed as the site
where most of the pathogenic PV auto-Ab bind [11, 19,
26, 27]. In addition, several of the relapsed patients showed
IgG reactivity against additional subdomains of Dsg3 most
of which had initially disappeared upon treatment with
rituximab. Of note, IgG reactivity against the COOH-
terminal EC5 subdomain of Dsg3 was not observed in
relapsed patients. This region which is located close to the
keratinocyte cell membrane is presumably not a target for
pathogenic auto-ab in PV [11]. Thus, IgG reactivity against
distinct regions of the Dsg3 subdomain which was abolished
by rituximab treatment reappeared in these patients at the
time of clinical relapse strongly suggesting that the repertoire
of Dsg3-speciﬁc B cells was only temporarily deleted by
rituximab treatment. The frequent detection of Dsg3EC1-
speciﬁc IgG in clinically relapsed PV patients supports the
concept that pathogenic PV auto-ab preferentially target the
NH2-terminal EC1 domain of Dsg3. The relative pathogenic
role of IgG against Dsg3 subdomains other than Dsg3EC1
awaits further analysis.
The majority, that is, 16/22PV patients, were successfully
controlled by treatment with rituximab and prednisolone
over 12 and 24 months, respectively. The other 6 patients
showed a clinical relapse during the observation period. Our
ﬁndings with rituximab are in line with previous reports
demonstrating an excellent clinical response associated with
a strong reduction of Dsg1- and Dsg3-speciﬁc IgG levels on
adjuvant treatment with rituximab [2, 25].
Of note, clinical improvement of mucosal and skin
lesions of the rituximab-treated PV patients was signiﬁcantly
associated with a decrease of IgG auto-ab titers. However,
we did not ﬁnd any signiﬁcant correlation between IgG
against distinct subdomains of Dsg3 and skin or mucosal
involvement. However, our ﬁndings suggest that IgG against
the Dsg3EC1 domain is associated with active PV as shown
earlier by our group and others [5, 8, 11, 23]. The Dsg3
recombinants of the present studies may not contain all the
conformational epitopes that are relevant in the immune
pathogenesis of pemphigus. However, as proven in two
recent reports, these ﬁndings with these Dsg3 recombinants
are valid and show diﬀerential reactivity against distinct
portions of the Dsg3 ectodomain in diﬀerent pemphigus
patients and diﬀerent diseases stages [8, 23].
Recently, we found a signiﬁcant correlation between IgG
reactivity against the Dsg3EC1 and the extent of clinical
involvement in PV [8]. IgG against the Dsg3EC1 was
seen preferentially in PV patients with muco-cutaneous
involvement but not in patients with either mucosal or skin
involvement only [8]. IgG auto-ab from pemphigus sera are
suﬃcient to cause blistering in human skin in vivo and in
vitro[12,13]bydirectinterferencewithDsgtransinteraction
binding sites [14–17].
Previous studies showed that IgG against the NH2-
terminus of the Dsg3 ectodomain is pathogenic [18].
Aﬃnity-puriﬁed IgG from sera of PV patients injected into
neonatal mice which were reactive with the EC1 and EC2 of
Dsg3 induced suprabasilar acantholysis, while IgG reactive
with the EC3-5 of Dsg3 did not [10]. AK23, a mouse
monoclonal ab against Dsg3 which targets the predicted
binding motif of the Dsg3EC1, has been shown to be
pathogenic in vivo whereas IgG that targets other parts of
the Dsg3 ectodomain was not [5, 19]. Additionally, AK23, is
able to directly interfere with homophilic Dsg3 binding [20]
whichsupportsthehypothesisthatauto-abfromPVpatients
directly inhibit Dsg3-mediated epidermal cell adhesion
[21].
Sekiguchi et al. suggested that, both pathogenic and
nonpathogenic auto-ab exist in PV [5]. This heterogene-
ity among anti-Dsg3 antibody due to speciﬁc epitope
recognition was previously demonstrated [19]. In addition
to pathogenic IgG auto-ab against Dsg3EC1, IgG against
additional Dsg3 subdomains, that is, DsgEC2, DsgEC3, and
Dsg3 EC4, may not be pathogenic per se but may act
synergistically in inducing the pathology of intraepidermal
loss of adhesion [8]. This contention is supported by a recent
study showing that nonpathogenic monoclonal IgG ab that
recognize regions of the Dsg3 ectodomain other than the
NH2-terminus induce desmosomal loss of adhesion when
injected together into mice [28].
Further studies are necessary to investigate the dynamics
of pathogenic IgG against the Dsg3EC1 and auto-ab against
other Dsg3 subdomains in the immune pathogenesis of
PV. At present, it remains to be elucidated why rituximab
only temporarily depletes pathogenic auto-ab in PV. Pre-
vious observations from our laboratory strongly suggest
the presence of short-lived, Dsg3-reactive plasma cells since
rituximab rapidly reduced Dsg3-speciﬁc IgG auto-ab but not
IgG against recall antigens such as tetanus toxoid, Epstein
Barr virus or inﬂuenza virus [29, 30]. Based on the present
and previous observations, detection and monitoring of IgG
against the Dsg3EC1 may be a more sensitive marker of
disease activity in patients with PV than monitoring IgG
against the entire Dsg3 ectodomain.
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